New nanomedicine for treating prostate cancer using advanced imaging techniques
Molecular imaging of novel PARP inhibitor nanomedicine delivery
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10892840
This study is testing a new way to deliver a special cancer-fighting medicine directly to tumors in men with advanced prostate cancer, aiming to make the treatment work better and cause fewer side effects, while also using a special imaging tool to see how well the medicine is reaching the cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10892840 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel nanomedicine that delivers a PARP inhibitor specifically for treating metastatic castration-resistant prostate cancer. The approach involves creating a unique drug delivery system that enhances the effectiveness of the treatment while minimizing side effects. Additionally, a companion imaging tool will be developed to visualize how well the nanomedicine reaches the tumors. The research will be conducted using both animal models and initial tests in human patients to evaluate the delivery and effectiveness of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer, particularly those with specific genetic mutations that may respond to PARP inhibitors.
Not a fit: Patients with early-stage prostate cancer or those who do not have the genetic mutations targeted by PARP inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted treatments for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in using PARP inhibitors for prostate cancer, indicating that this approach could build on existing knowledge and potentially lead to significant advancements.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VANBROCKLIN, HENRY F. — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: VANBROCKLIN, HENRY F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, Cancer Patient, CancerModel, Cancers